A short-term randomized clinical trial of daily versus alternate day use of
travoprost 0.004% in the treatment of ocular hypertension.
Author(s): Khairy HA(1), Said-Ahmed K.
Affiliation(s): Author information:
(1)Ophthalmology Department, Minoufiya University Hospital, Menoufiya, Egypt.
khairyhany@hotmail.com
Publication date & source: 2013, J Glaucoma. , 22(2):123-6
PURPOSE: To compare the daily versus the alternate day use of travoprost 0.004%
in lowering the intraocular pressure (IOP) in patients with ocular hypertension.
METHODS: Fourteen patients with ocular hypertension in both eyes have been
randomly assigned to receive travoprost 0.004% once a day in 1 eye and once every
other day in the other eye. The main outcome measure was change in the mean of
the IOPs measured at 9:00 AM, and 4:00 PM between baseline (before treatment) and
measurement of IOPs at 1, 2, 4, 8, and 12 weeks after treatment.
RESULTS: After 3 months of treatment, daily use of travoprost 0.004%
significantly reduced IOP (mean±standard error of mean) by 6.1±0.5 mmHg (P<0.001)
and alternate day use by 5.9±0.3 mmHg (P< 0.001) adjusted from an overall
baseline of 24.3±0.5 mm Hg. The difference in the IOP-lowering effect was not
statistically significant (P<0.05).
CONCLUSIONS: Alternate day use of travoprost 0.004% was as safe and effective as
its daily use in lowering the IOP in patients with ocular hypertension.
|